June 16 (Reuters) - iBio Inc IBIO.O:
IBIO INITIATES NON-HUMAN PRIMATE STUDY OF FIRST-IN-CLASS ACTIVIN E ANTIBODY FOLLOWING POSITIVE PRECLINICAL DATA DEMONSTRATING PREVENTION IN WEIGHT REGAIN AFTER GLP-1 TREATMENT
IBIO INC - IBIO-610 DRIVES 8.9% BODY WEIGHT LOSS IN MICE
IBIO INC - PRECLINICAL RESULTS SHOW 26% FAT REDUCTION WITH IBIO-610
IBIO INC - IBIO-610 PREVENTS WEIGHT REGAIN IN MICE AFTER GLP-1 THERAPY
Source text: ID:nGNXwP591
Further company coverage: IBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.